Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced the appointment of Karen L. Noblett, M.D., M.A.S., a urogynecologist and prolific clinical researcher, as Chief Medical Officer.
Dr. Noblett is world renowned for her work in female pelvic medicine with an emphasis on sacral neuromodulation for the treatment of patients with refractory overactive bladder, urinary retention and bowel dysfunction.
“Since early 2014, Dr. Noblett has been a highly valuable and engaged collaborator in the development of Axonics’ rechargeable SNM system,” stated Raymond W. Cohen, Chief Executive Officer. “We are extremely fortunate to have a physician of Dr. Noblett’s expertise, judgement and integrity join our leadership team. We envision that, among other things, Dr. Noblett will make a significant contribution to the conduct of our U.S. pivotal study, anticipated to begin in Q4 of this year.”
Dr. Noblett joins Axonics having spent the last three years as the founding Chair of the Department of Obstetrics and Gynecology at the University of California, Riverside, School of Medicine. In the previous 20 years, she served as a clinical professor, practicing physician, fellowship director and Chief Medical Officer at the University of California, Irvine. With over 40 peer-reviewed journal articles, numerous book chapters and dozens of abstracts to her credit, Dr. Noblett has established herself as a thought leader in her field. She will continue to serve in academic leadership roles with the American Urogynecology Society and the American Board of OB/GYN.
“Axonics’ vision is to provide high-quality, innovative technology that simplifies care for patients with refractory pelvic floor dysfunction and reduces healthcare costs,” commented Dr. Noblett. “From the onset of the project, I’ve been impressed with the dedication to excellence and the outstanding caliber of the entire Axonics team, and I am honored to have been selected as the Company’s Chief Medical Officer.”
Of note is Dr. Noblett’s clinical research in sacral neuromodulation and manuscript (InSite study) titled, “Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim® therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder,” which was published in the journal of Neurourology and Urodynamics in 2014.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction and can be further directed towards other clinical indications. The Axonics r-SNM system includes a miniaturized rechargeable implantable stimulator qualified to function at least 15 years, a charging system optimized for reduced charge time with no heating, a patient-friendly remote control and an intuitive clinician programmer that facilitates the lead placement procedure and programming. During 2016, the Axonics r-SNM system gained regulatory approval in Europe and Canada for the treatment of overactive bladder, urinary retention, and fecal incontinence. For more information, visit the Company’s website at www.axonicsmodulation.com
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6322
Chief Operating & Financial Officer
Pure Communications, Inc.
Matt Clawson, +1-949-370-8500
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
OCP-S.A.22.11.2017 18:01 | pressemeddelelse
OCP Announces Date of 2017 Third Quarter and Nine Month Results
TATA-MOTORS22.11.2017 15:48 | pressemeddelelse
Tata Motors Charts Out 'Connecting Aspirations' As Its New Corporate Brand Identity in Global Markets
L&T-TECHNOLOGY-SERVICES22.11.2017 14:52 | pressemeddelelse
NelsonHall Positions L&T Technology Services in the Leaders Category for IoT Services
APR22.11.2017 11:32 | pressemeddelelse
Mundipharma and APR Applied Pharma Research S.A Announce a New Alliance for the Distribution of Nexodyn® AcidOxidizing Solution in Africa and the Levant
SMITHERS-VISCIENT22.11.2017 11:32 | pressemeddelelse
Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry.
EURID22.11.2017 10:02 | pressemeddelelse
The .eu Web Awards Shine Again in 2017 with the Announcement of the Winners
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum